Ozempic's FDA safety reports pile up while Wegovy's stay empty

Key details

Ozempic carries 699 vision loss reports and 460 gastroparesis reports in the trailing twelve months, while Wegovy shows zero in all six tracked categories.
Both products are semaglutide, so the gap is far more likely to be about how reports get named than about the medicine.
A report in the FDA database records a suspicion, not a proven cause, and anyone can file one.
Severe nausea, vomiting and dehydration are the most reported problems across every GLP-1 in the database, running into the thousands for Mounjaro and Zepbound.

16 developments affecting GLP-1 access were tracked on Sunday, September 13, 2026, across 2 categories. Each entry links to the full record.

## FDA and safety

**[673 stomach-paralysis reports filed for Ozempic in one year](/fda/faers-ozempic-gastroparesis)**. 673 reports of serious stomach-slowing side effects for Ozempic were filed with the FDA in the past year, but these reports don't prove Ozempic caused them.

**[757 vision loss reports filed for Ozempic in one year](/fda/faers-ozempic-naion)**. 779 vision-related side effect reports for Ozempic were filed in the past year, but reports alone do not prove the drug causes these problems.

**[210 pancreatitis reports tied to Ozempic in FDA database](/fda/faers-ozempic-pancreatitis)**. The FDA's report database logged 221 pancreatitis complaints tied to Ozempic in one year, but that number alone does not prove Ozempic causes pancreatitis.

**[37 thyroid cancer reports tied to Ozempic in one year](/fda/faers-ozempic-thyroid-cancer)**. 37 thyroid cancer reports linked to Ozempic were filed with the FDA in the past year, but reports alone don't prove the drug caused cancer.

**[95 reports of suicidal thoughts linked to Ozempic in FDA database](/fda/faers-ozempic-suicidal-ideation)**. The FDA has logged 95 reports linking Ozempic to suicidal thoughts or self-harm in the past year, but a report does not prove the drug caused it.

**[2,800+ reports of severe nausea and dehydration tied to Ozempic](/fda/faers-ozempic-severe-nausea)**. Nearly 2,800 reports of severe nausea, vomiting, and dehydration linked to Ozempic have been filed with the FDA in the past year, but reports alone don't prove the drug caused the problem.

**[No stomach paralysis reports linked to Wegovy in past year](/fda/faers-wegovy-gastroparesis)**. In the past 12 months, zero reports of gastroparesis or related stomach-paralysis conditions for Wegovy were logged in the FDA's safety database.

**[No vision-loss reports filed for Wegovy in 12 months](/fda/faers-wegovy-naion)**. In the past 12 months, zero vision-loss reports for Wegovy were filed in the FDA's safety database.

40 further items in this category were tracked today and are listed on the site.

## Research and trials

**[New diabetes drug to rival semaglutide in 2028 trial](/fda/clinical-trial-nct07653477)**. A new injectable diabetes drug is being tested against semaglutide, but it is years away from any possible approval.

**[Can semaglutide protect the brain after a stroke?](/fda/clinical-trial-nct07511543)**. A large Phase 3 trial will test whether semaglutide helps protect the brain after a stroke, it has not started yet.

**[Study tests semaglutide for prostate cancer patients](/fda/clinical-trial-nct06908694)**. A small Canadian study is recruiting men with prostate cancer to test whether semaglutide helps manage side effects of hormone therapy.

**[Pakistan study will test tirzepatide in South Asian patients](/fda/clinical-trial-nct07728318)**. A small research study in Pakistan will test tirzepatide in South Asian patients with type 2 diabetes and obesity, it has not started yet.

**[Eli Lilly tests add-on drug for people whose GLP-1s aren't working](/fda/clinical-trial-nct06897475)**. Eli Lilly is testing a new add-on diabetes drug for people whose blood sugar isn't controlled on semaglutide or tirzepatide.

**[Danish trial tests GLP-1 drugs for atrial fibrillation and weight loss](/fda/clinical-trial-nct07816744)**. A Danish trial will test whether GLP-1 drugs help reduce atrial fibrillation progression in people with obesity, starting October 2026.

**[Novo Nordisk tests switching semaglutide patients to Cagrisema](/fda/clinical-trial-nct07817251)**. Novo Nordisk is testing whether people on semaglutide can safely switch to a new three-drug combination called Cagrisema for type 2 diabetes.

**[Eli Lilly begins pediatric tirzepatide trial for children ages 6 to 12](/fda/clinical-trial-nct07817875)**. Eli Lilly is testing tirzepatide in children ages 6 to 12 with obesity; enrollment starts September 2026.

1 further item in this category were tracked today and are listed on the site.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.